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Abstract
Background: Alterations on glucose consumption and biosynthetic activity of amino acids, lipids and nucleotides are
metabolic changes for sustaining cell proliferation in cancer cells. Irrevocable evidence of this fact is the Warburg effect
which establishes that cancer cells prefers glycolysis over oxidative phosphorylation to generate ATP. Regulatory action over
metabolic enzymes has opened a new window for designing more effective anti-cancer treatments. This enterprise is not
trivial and the development of computational models that contribute to identifying potential enzymes for breaking the
robustness of cancer cells is a priority.
Methodology/Principal Findings: This work presents a constraint-base modeling of the most experimentally studied
metabolic pathways supporting cancer cells: glycolysis, TCA cycle, pentose phosphate, glutaminolysis and oxidative
phosphorylation. To evaluate its predictive capacities, a growth kinetics study for Hela cell lines was accomplished and
qualitatively compared with in silico predictions. Furthermore, based on pure computational criteria, we concluded that a
set of enzymes (such as lactate dehydrogenase and pyruvate dehydrogenase) perform a pivotal role in cancer cell growth,
findings supported by an experimental counterpart.
Conclusions/Significance: Alterations on metabolic activity are crucial to initiate and sustain cancer phenotype. In this
work, we analyzed the phenotype capacities emerged from a constructed metabolic network conformed by the most
experimentally studied pathways sustaining cancer cell growth. Remarkably, in silico model was able to resemble the
physiological conditions in cancer cells and successfully identified some enzymes currently studied by its therapeutic effect.
Overall, we supplied evidence that constraint-based modeling constitutes a promising computational platform to: 1)
integrate high throughput technology and establish a crosstalk between experimental validation and in silico prediction in
cancer cell phenotype; 2) explore the fundamental metabolic mechanism that confers robustness in cancer; and 3) suggest
new metabolic targets for anticancer treatments. All these issues being central to explore cancer cell metabolism from a
systems biology perspective.
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Introduction
In recent years we have witnessed significative advances for
identifying and understanding the role that individual genes have
in genesis, development and progression on cancer [1]. However,
despite significant advances in genomic sciences in identifying
oncogenes and tumor suppressors, a systemic explanation of how
these genes deregulate the normal function of genetic circuits and
how its control may be used to design effective drugs against
cancer still remains a great challenge in systems biology
[2,3,4,5,6].
In conjunction with this molecular view of cancer, detailed
studies monitoring the metabolic alterations in cells are a
promising avenue for understanding and controlling cell prolifer-
ation in cancer cells [2,7,8]. For instance, researchers have
extensively studied the p53 tumor suppressor’s ability to trigger
DNA repair, cell cycle arrest and apoptosis, but recently p53’s
capacity to influence mitochondrial respiration and energy
metabolism have been elucidated [9,10]. Similarly, enhanced
effect on glycolysis, lactate (lac) production and control of fatty
acids oxidation originated by Hypoxia inducible factors (HIF) and
LKB1 tumor suppressor are clear examples linking genes
expression, metabolism and cancer phenotype [3].
In this contextual scheme, development of computational
procedures capable of surveying the physiological responses on
cancer cells in terms of its metabolic topology and genetic
information constitutes an attractive strategy for understanding,
characterizing, designing and improving effectiveness of cancer
drugs [11]. In this work we present a constraint-based analysis of a
metabolic network integrated by a core of metabolic pathways
participating in cancer cell growth: glycolysis, TCA cycle, pentose
phosphate pathways (PPP) and oxidative phosphorylation. Constraint-
based modeling has proven to be a successful paradigm in systems
biology for describing and exploring the phenotype capacities for a
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metabolic topology [11,12,13,14,15].
This paper’s centralaim is twofold: 1) the construction of a model
simulating metabolisms that serves as a computational framework
auxiliary to describe and understand physiological behavior in
cancer cells; and 2) the identification of potential metabolic targets
to induce a reduced phenotype on cancer cell growth. To
qualitatively assess the in silico results obtained from our metabolic
reconstruction with those experimentally observed, we accom-
plished a study of growth kinetics for Hela cell line. Furthermore,
based on computational criteria we identified some enzymes with a
relevant influence on cell growth and compared them with those
considered as potential therapeutic targets in the literature.
Overall, we supply evidence that constraint-based modeling can
be used as a platform for unraveling the biochemical mechanism
underlying cancer cell growth and potentially contribute toward
designing strategies for clinical treatments in cancer.
Results
Core Metabolism in cancer cells
Ever since the pioneering observation that aerobic glycolysis in
cancer [7] is preferred over oxidative phosphorylation as a mechanism
to generate ATP from glucose, numerous experiments have
supported and extended the significant role that metabolisms
have on transformation, proliferation, angiogenesis and metastasis
in cancer [16,17,18]. Thus, scanning human tumors with positron
emission tomography (PET) [17] has verified that a high uptake rate of
glucose constitutes a hallmark in cancer cells, presumably required
to confer adaptive advantages when facing acidic and hypoxic
environments [19].
In light of these observations, an explanation of why energy
production relies on glycolysis instead of on the more effective
pathway driven by oxidative phosphorylation in mitochondria [2,16]
requires computational models capable of taking into account not
only both pathways but a robust metabolic network containing its
metabolic interconnectivity.
Keeping in mind this systemic view, we constructed a metabolic
network with those metabolic pathways that have a pivotal role in
cancer cell growth: glycolysis, TCA cycle, pentose phosphate, glutamino-
lysis and oxidative phosphorylation [3,16]. According to reconstruction
protocols, our network was based on published knowledge about
metabolism in cancer cells, basic thermodynamics and compart-
mentalization information associated with each metabolic reaction
inside the cell, see Table S1. Thus, for example, studies on C
13
NMR spectroscopy have demonstrated that glutaminolysis consti-
tutes an active metabolic pathway in human glioblastoma cell lines
[8], and consequently, a demand reaction of a-ketoglutarate
representing an intermediary compound along the conversion of
glutamine to lactate was included in the reconstruction. In
addition, the reconstruction was complemented by transport
reactions to resemble the physiological conditions prevailing in
cancer cells, particularly those associated with glucose consumption,
lactate production and hypoxia conditions, see Table S1. Overall, our
reconstruction integrates 66 metabolites participating in 80
metabolic reactions representing glycolysis, pentose phosphate, TCA
cycle, oxidative phosphorylation and glutaminolysis, as well as transport
reactions of essential metabolites for cellular proliferation,
specifically oxygen, hydrogen, carbon dioxide and water, see Table S1
in supplementary material. Figure 1 depicts the metabolic network
used in this study. Mathematical representation of this set of
reactions, through the stoichiometric matrix, constitutes our
central platform for exploring and estimating the metabolic
capacities potentially driving cancer cells [3,16].
Dynamic Constraint-based Modeling and its
experimental assessment
Experimental assessment of the results and hypothesis inferred
from computational modeling is needed to ensure a high-quality
metabolic reconstruction with a real scope for explaining and
predicting cell behavior. Given that self-sufficiency in growth
signals and mechanisms for evading apoptosis [20] in cancer cells
contribute to uncontrolled cell proliferation, the feasibility of our
model to simulate cancer cell growth constituted a principal issue
to evaluate. Therefore, dynamic constraint-based modeling was
applied to the metabolic reconstruction depicted in Figure 1.
According to this formalism, growth rate is calculated by assuming
the existence of a characteristic time scale, at which a steady state
condition for metabolite concentrations is a plausible assumption.
Thus, hypothesizing that physiological growth rate at each time
scale obeys optimization principles, linear programming was
applied to identify the metabolic flux profile that maximized a
function associated with growth rate [21], see methods section.
Malignant progression requires proper metabolic cell machinery
in order to supply the energy and biosynthetic demand required for
cancer cell growth. To quantify the cancer cell growth in terms of its
metabolic networks and to link the topology of the reconstruction
with the cancer cell physiology, we proceeded to construct an
objective function that mathematically represents the metabolic
demands required for successful cell growth [11,13,22,23].
The proper selection of an objective function is crucial for
reducing the steady-state stoichiometrically feasible solution to an
optimal solution space [22,24]. In this work the objective function
was created by taking into account the expected metabolites
supporting cancer cell proliferation [25]. Thus, based on a review
of literature and considering the set of metabolites integrating our
reconstruction, we suggest an objective function consisting of lactate
(lac), ATP, ribose 5-phosphate (r5p), oxaloacetate (oaa) and citrate(cit)
production, having been selected according to their fundamental
roles as 1) precursors required for energy production, 2) precursors
of amino acids and nucleotides and 3) intermediates in
maintaining glycolysis and the reductive power required for
biosynthesis of other cellular compounds [25,26]:
OF~lactate e ðÞ zATP czm ðÞ zr5pm ðÞ zNAD m ðÞ
zNADPH m ðÞ zoxaloacetate m ðÞ zcitrate m ðÞ ,
where c, e and m denote the compartments utilized in the
reconstruction (cytoplasm, external environment and mitochondria
respectively).
In addition, proper computational representation of environ-
mental conditions is essential to obtain reliable results and
interpretations from in silico procedures [24]. Hence, sink and
demand reactions were included to define proper metabolic
boundaries to mimic the physiological conditions prevailing
around cancer cells, see Table S1. Through sink reactions (which
serve to introduce those metabolites that are produced or
consumed by nonmetabolic cellular processes), we represent
NADH, NAD, CO2, biphosphate, hydrogen, water, carbon dioxide, coenzyme
A, FAD and FADH2. In turn, through demand reactions (which are
unbalanced reactions that permit the accumulation of a compound
otherwise not allowed in steady-state models because of mass-
balancing requirements), we were able to include a source of
ACCOA, ADP and oxygen.
Furthermore, plasma, an abundant source of glucose and
glutamine in cancer cells, was represented by two demand
reactions in the reconstruction, see Figure 1 and Table S1. In
order to simulate glucose consumption, a simple transport of
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consumption on glutamine was represented through an external
source of 2-oxoglutarate, one of the intermediary products of the
glutaminolysis pathway in cancer cells, see Figure 1 [8].
Finally, consistent with hypoxia conditions governing cancer cell
environment, all the simulations were constrained to low rates of
oxygen uptake [27], see details in Table S1.
Constraint-base modeling assessment : Evaluating
Objective Function
To evaluate the physiological significance of the proposed
objective function, we decided to explore the extent to which
growth rate derived from dynamic constraint-based modeling
coincided with that obtained from a kinetic growth study of Hela
cell lines. Therefore, the in silico temporal profile of growth rate
was calculated by defining an initial cellular density, an initial
available glucose concentration and a proper time scale for
assuming steady-state condition, see methods section. Meanwhile,
Hela cancer cell lines were cultivated in solution and a growth
kinetic study was accomplished. As described in the methods
section, experimental measurements of cellular density on Hela
cells were made with six replicates for estimated experimental
reproducibility and by monitoring the process every 24 hours for
five days, see also Figure 2 (B).
The contribution of metabolic entities in the objective function
has been assumed to carry equal weight on growth rate, in such a
way that instead of using a quantitative criteria to evaluate the
crosstalk between experiment and modeling, a qualitative
procedure based on the normalization of cellular density profile
was implemented. Thus, proceeding as described in the methods
section, we found that our modeling was capable of obtaining a
normalized temporal growth profile comparable with that
associated with Hela cell lines, see Figure 2.
In light of this result, we postulate that the objective function
associated with the metabolic reconstruction depicted in Figure 1 is
potentially able to elucidate the metabolic flux activity required for
supplying the metabolic demand for cancer cell growth. This is a
crucial contribution in this study and constitutes the backbone for
exploring the relationships among gene activity, metabolism and
phenotype in cancer.
Figure 1. Metabolic pathways with a significant role in cancer cells. As a result of a bibliography search, we have selected those metabolic
pathways that potentially can constitute a metabolic core on most cancer cells. Orange, red and green dashed lines indicate metabolites that
participate in other biosynthetic pathways, metabolites that can be transported from cytoplasm to mitochondrion and metabolites that can be
transported from mitochondrion to cytoplasm, respectively. Compartment information has been denoted by external environment [e], cytoplasm [c]
and mitochondria [m]. The set of reactions that integrates this reconstruction are listed in Table S1.
doi:10.1371/journal.pone.0012383.g001
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Computational models on biological systems have two general
purposes: 1) to reproduce what is physiologically observed and
understand their biological principles, and 2) to create a platform
capable of predicting the cellular phenotype when metabolic
alterations are induced in the system. Having verified that in silico
phenotype qualitatively reproduces the growth rate of Hela cell
lines, we proceeded to survey the metabolic mechanisms
supporting cell proliferation through Flux Balance Analysis (FBA),
an in silico formalism that has been useful in exploring the
genotype-phenotype relation for a variety of organisms [11,12,13,
22,23,28]. Specifically, we have used our metabolic reconstruction
for identifying those biochemical reactions that have a strong
influence on controlling cancer cell growth, a worthy issue when
one desires to identify metabolic targets with effective results in
cancer treatments [6]. For this purpose, metabolic targets with a
central role in cancer cell growth were identified by two
constraints: low flux variability and high enzymatic essentiality for
cancer cell growth. Together, these constraints constitute compu-
tational criteria for selecting those reactions that ensure a low
redundancy on metabolite synthesis with a maximal effect for
decreasing its phenotype. Thus, this computational criteria lead us
to identify a set of target enzymes whose metabolic activity may
has a direct effect on cancer cell growth, see Figure 3.
The robustness of this set of target enzymes in terms of the ratios
among the objective function’s components was subsequently
verified: We repeatedly applied the in silico analysis to a set of
objective functions whose equimolar contributions on objective
function’s components were not assumed. With this in mind, 1,000
objective functions (with components selected from a random
uniform distribution ranging from 0 to 1 around numerical values
estimated for other organisms [22]) were reconstructed, and
enzymes with low flux variability and high enzymatic essentiality were
identified in each realization. Despite growth rates highly
dependent on the ratios of the objective function’s components,
we identified a set of enzymes that in 99% of all the realizations
obeyed selection criteria, see Figure 4. Among the target enzymes
identified in silico, we determined that some participate in glycolysis,
such as phosphoglucomutase (PGMT), enolase (ENO), glyceraldehyde-3-
phosphate dehydrogenase (GAPD), pyruvate kinase (PYK) and lactate
dehydrogenase (LDH). Consistent with this result, development of
drugs mainly targeting glucose transport and phosphorylation
steps in glycolytic pathways have shown to be a latent therapeutic
strategy for reducing cancer phenotype [19,27,29].
Furthermore, constraint-based modeling suggests that lactate
dehydrogenase can be used as a metabolic control point over
phenotype behavior in agreement with previous studies, see Figure 5
[2,3]. Specifically, there has been experimental evidence that
inhibition of lactate dehydrogenase induces a decreased activity of
some glycolytic enzymes and consequently reduces growth rate in
cancer cells [30]. Motivated by this fact and with the purpose of
further assessing our computational interpretation, we evaluated to
what extent a reduction of enzymatic capacity of lactate dehydrogenase
influences the metabolic activity on enzymes participating in
glycolysis, pentose phosphate and TCA cycle.A sFigure 5 shows (panel A,
B and C), flux balance analysis exhibits that an increment on
enzyme activity for lactate dehydrogenase is followed by an increased
metabolic activity over glycolysis and some enzymes participating in
TCA cycle and pentose phosphate pathway. Consistent with this in silico
observation, an increase of lactate production has been proposed to
be a necessary condition supporting tumor cell transformation
through the Warburg effect [31]. To confirm that this property is a
consequence of the geometry of the flux steady-state solution space
and not of the particular selections of ratios in the objective
function’s components, a nonbiased Monte Carlo sampling
method was applied for characterizing the solution spaces [23],
Figure 2. Temporal profile of kinetic cell growth. (A) Comparative analysis between the growth rate obtained experimentally and in silico. (B)
Average and standard deviation obtained in the kinetics measurements for Hela cell lines. As described in methods, growth rate was monitored every
24 hours for five days, and six replicates were obtained for each absorbance measurement. Statistical properties characterizing the kinetic growth on
Hela cell lines are shown in Figure 2(B), while the temporal behavior of glucose uptake rate and external concentration predicted by in silico
procedures are depicted in (C) and (D), respectively. Coefficients of variation obtained at each measurement are reported by the red points in (B).
doi:10.1371/journal.pone.0012383.g002
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correlation emerged between metabolic activity of lactate
dehydrogenase (LDH) and the first enzyme in glycolysis:
phosphoglucomutase (PDGM). A decrease of LDH tends to be related
with a decrease on glucose metabolism through PDGM, hence, our
in silico analysis suggests LDH as a control point in cancer cell
metabolism.
On the other hand, our computational platform suggests that
pyruvate dehydrogenase (PDHm) can perform a central role in driving
cell proliferation due to its low flux variability and high enzymatic
essentiality for metabolism in cancer cell growth, see Figure 4 (A).
Consistent with this finding, there is evidence that metabolic
inhibition of PDHm contributes to Warburg metabolism and
enhances malignant phenotype in human neck and head
squamous carcinomas [26,32]. This observation could make sense
in light of additional regulatory components integrating this
metabolic puzzle. First, hypoxia condition in tumors induces the
activation of HIF (Hypoxia Inducible Factor), which in turn activates
pyruvate dehydrogenase kinase 1, an enzyme that negatively regulates
the catalytic activity of PDHm. In addition, aerobic glycolysis is
enhanced by the fact that HIF induces the overproduction of
enzymes participating in the glycolytic pathway and lactate
production [31]. Overall, enhancement of the Warburg effect
and diminishing activity of PDHm seems to be a metabolic
response that confers selective advantage for survival and cell
proliferation.
With the purpose of surveying how growth in cancer cells may
vary when changing the metabolic activities on both PDHm and
glucose transport, we have accomplished phenotypic phase plane analysis,
a computational procedure to visually explore how objective
function behaves when flux variations over two independent
metabolic reactions occurs [21,23]. Remarkably, as Figure 6 (B)
shows, our analysis suggests that at fix glucose uptake rate a
decrease on PDHm enzymatic activity may improve the phenotype
growth rate in cancer cell lines, arrow in region I. Despite the fact
that this result is in agreement with some experimental reports, our
computational model predicts the existence of a threshold on
PDHm whose reduced activity could be beneficial to arrest cancer
cell growth (region II), a result that requires posterior experimental
verification.
Optimization of the objective function leads us to conclude that
glutaminolysis, starting at glutamine uptake rate and ending with
lactate production, is an active pathway during cancer cell growth.
From a functional and biological point of view, glutaminolysis
performs a fundamental role in replenishing TCA cycle and
generating additional reductive power required for fatty acids
biosynthesis. Furthermore, our in silico analysis suggests that
fumarate hydratase (FUMm) and succinate dehydrogenase (SUCD1m) can
be independently used as metabolic targets for regulating cell
proliferation, see Figure 6A and C. Phenotype phase plane
accomplished over these enzymes allows us to conclude that when
activity of FUMm (SUCD1M) is reduced different regions separated
Figure 3. Flux Variability and Enzyme essentiality on metabolic reactions. To identify those reactions that could have a pivotal role in
cancer growth rate, flux variability and enzyme essentiality analysis were accomplished over all the reactions included in the reconstruction. In panel
(A), the metabolic reactions whose deletion produces a significant reduction on growth rate are highlighted in red. Those reactions that ensure a low
variability and high essentiality constitute 27% of the complete metabolic reconstruction and these appear in red in panel (B). Exchange and sink
reactions were excluded from this analysis. Abbreviation code: Enolase (ENO), glyceraldehyde-3-phosphate dehydrogenase(GAPD), phosphoglucomutase
(PGMT), pyruvate kinase (PYK), triose-phosphate isomerase (TPI), lactate dehydrogenase (LDH), ribose-5-phosphate isomerase (RPI), pyruvate
dehydrogenase (PDHm), 2-oxoglutarate dehydrogenase (AKGDm), cytrate synthase (CSm), Fumarate hydratase (FUMm), malate dehydrogenase (MDHm),
succinate dehydrogenase (SUCD1m), succinyl-CoA synthetase (SUCOAS).
doi:10.1371/journal.pone.0012383.g003
Modeling Cancer Metabolisms
PLoS ONE | www.plosone.org 5 August 2010 | Volume 5 | Issue 8 | e12383by a threshold value are identified. As can be appreciated in
Figure 6 (A) and (B), when metabolic activity on FUMm or
SUCD1M is decreased, phenotype growth rate in region I is
enhanced while in region III is reduced. Interestingly, phenotype
behavior observed in region I is in accordance with the fact that
FUMm or SUCD1m can participate as a tumor suppressor when its
enzymatic activity is deficient [33]. Even though the model can
sense the influence that the enzymatic activity of FUMm or
SUCD1m has on cancer growth rate, further analysis is required to
assess if in silico interpretation on region II and III has a biological
meaning.
We highlight that in our simulations mitochondria-derived citrate
constitutes a fundamental metabolite to be optimized for
supporting cell proliferation. As a result, low citrate transport
from mitochondria toward cytoplasm induces a decreased effect
on in silico growth rate. Consistent with published findings,
inhibition of ATP citrate lyase participating in conversion of
mitochondria-derived citrate into acetyl-coenzyme A in cytoplasm
prevents cancer cell proliferation and tumor growth due to its
central role as a precursor for lipids [2,34]. Even though inhibition
of ATP citrate lyase and low citrate transport have the final effect of
reducing acetyl-coenzyme A, a more detailed analysis should be
considered in future reconstructions. Specifically, fatty acids
metabolism should be included in the reconstruction in order to
evaluate if cytoplasm acetyl-coenzyme A could be a more appropriate
component than cytoplasm citrate to simulate computationally
cancer cell growth.
The pharmaceutical design of drugs targeting the pentose phosphate
pathway (PPP) seems to be an appealing strategy to reduce growth
rate in cancer cells due to its essential role in synthesizing ribose-5-
phosphate (r5p), essential for biosynthesis of nucleotides and nucleic
acids [35]. To quantify the contribution of PPP to cancer cell
growth, we analyzed in silico how transketolase (TKT1) and glucose-6-
phosphate dehydrogenase (G6PDH), representing the nonoxidative and
oxidative branches in PPP respectively, affect cell growth pheno-
type, see Figure 5E. As Figure 3A shows, in silico mutation of TKT or
G6PDH predicts its nonessentiality in cancer cell growth, this due to
the fact that non-oxidative or oxidative branches in PPP can both
produce ribose-5 phosphate (r5p). Converse to this harmless effect of
simple mutations, however, in silico modeling suggests that
simultaneous mutation is lethal for phenotype in cancer cell growth,
a finding that agrees with already published reports. Thus,
enzymatic down-regulation of glucose-6-phosphate dehydrogenase
(G6PDH) and TKT1 is required to effectively arrest growth rate
Figure 4. Enzymes with high essentiality and low variability that are robust to the ratio of objective function’s components.
Reactions with high essentiality and low variability were identified through a set of 1000 objective functions with nonequivalent ratios among
function components. As panel (A) shows, reactions obeying both criteria (red on black regions) were plotted over the 1000 realizations. In each
realization, those enzymes that obey the in silico criteria were denoted in black; all others in white. The percentage of times reactions obeyed the
computational criteria are depicted in panel (B). Robust enzymes relevant to this study (excluding transporters, exchange and demand reactions)
were labeled in red. EX, DM and Sink denote exchange, demand and sink reactions in the cytoplasm [c] and mitochondria [m] compartments.
doi:10.1371/journal.pone.0012383.g004
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plane done with G6PDH and TKT1 allows us to infer not only that a
simultaneous reduction of TKT1 and G6PDH metabolic activity
clearly predicts a drop in growth rate but also that, although both
branches of PPP can produce r5p,t h eoxidative branch can be a
limitingfactorforgrowthrateincancer: itmeansifTKT1flux isnull
an increment of G6PDH metabolic activity can produce phenotype,
however the opposite situation does not occurs, see Figure 5(E),a
hypothesis that needs to be verified with more precise experimental
measurements [35].
All together, the complete set of benchmarks used for
supporting this reconstruction are shown in Figure 7. In light of
these results, our constraint-based modeling represents an effort to
construct a computational platform that serves as a guide for
accomplished descriptive and predictive analysis about cancer
metabolisms, thereby creating a dialogue with an experimental
counterpart.
High throughput technology and cancer variability
Previous sections were devoted to constructing a metabolic
network, simulating growth rate and evaluating its predictive scope
based on published findings about cancer cells. From a conceptual
view, metabolic activity resulting from our constraint-based
analysis in nature represents an average behavior obtained from
a cancer cell population whose variability and stochasticity on
phenotype have been neglected. However, it is well known that the
cancer cell population in tumors is heterogeneous, and a
subsequent question is, then, to what extent cancer cell diversity
in tumors can display heterogeneous metabolic activity [18]. A
significant contribution to this issue was published regarding a
cervical uterine cancer study. It concluded that significant
variability within tumor regions mainly is concentrated on genes
participating in transcriptional regulatory and metabolic mecha-
nisms [18]. Thus, with the purpose of estimating the extent of the
cellular heterogeneity inherent in tumors could affect the
metabolic activity of our reconstruction, we have done a statistical
analysis of more than 33 samples of expression profiling stored in
the GEO repository at NCBI (accession GSE5787) obtained from
several regions of 16 patients with cervical cancer [18]. In contrast
to the methodology used by the original report [18], our variability
analysis was quantified through classical statistics over the
expression data obtained from affymetrix technology, see methods
section. In agreement with the original findings that the expression
of genes acting on signal transduction, regulatory mechanism and
metabolic pathways was significantly varied, we obtained that
genes participating in oxidative phosphorylation potentially induce a
variability on enzymatic activity within the population, see Table
S2 in supplementary material.
Guided by this result, we conclude that even though some genes
involved in metabolism can be expressed quite variably in tumors,
expression profiling reported for cervical cancer may suggest that
most of the metabolic pathways included in this reconstruction are
Figure 5. Lactate dehydrogenase and its influence on central pathways. Lactate dehydrogenase (LDH) has been suggested as a pivotal
metabolic control on cancer cell growth with a significant role in the Warburg effect. Panels (A), (B) and (C) show the effects that variations of LDH
activity have on some enzymes participating in glycolysis, TCA cycle and pentose phosphate, respectively. Metabolic activity of LDH increases from
bottom to top. Panel (D) shows the correlation between flux activity of LDH and phosphoglucomutase (PGMT) obtained through sampling the null
space of the stoichiometric matrix. Phenotype phase plane for glucose-6-phosphate dehydrogenase (G6PDH) and transketolase (TKT1), enzymes
quantifying the activity of the oxidative and non-oxidative branches of pentose phosphate, is depicted in panel (E). White arrows indicate the
direction at which the metabolic flux increases.
doi:10.1371/journal.pone.0012383.g005
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oxidative phosphorylation. Computational and experimental assess-
ment for verifying this heterogeneity and exploring its biological
consequences will be an issue to address in future.
Discussion
Metabolic alterations constitute a hallmark in cancer cells: They are
required for driving transformation, progression and spreading cancer
in tissues [16]. Consequently, development of computational
procedures for identifying those enzymes with an influential role on
cancer cell growth constitutes an active line of research essential to
establishing the bases of a rationalized design of drugs with the desired
therapeutic effects [16]. In our study, a metabolic reconstruction
integrating the best-known metabolic pathways participating in cancer
development was accomplished: glycolysis, pentose phosphate pathway,
oxidative phosphorylation, glutaminolysis and TCA cycle.
To assess the practical scope of the metabolic reconstruction,
four criteria were evaluated: 1) the model’s ability to simulate
growth rate in Hela cells, 2) its ability to identify the global
metabolic activity during cell proliferation; 3) the expected
phenotype on growth rate when variations on enzymatic activity
are induced; and 4) the effect that cancer heterogeneity has on
metabolic reconstruction. Qualitative assessment of points 1 to 3,
summarized by Figure 2 and 6, were successfully evaluated in silico
and have led us to suggest that constraint-based modeling can be
used as a descriptive and predictive framework to study the
metabolic alterations supporting cancer in cells.
Although this computational study constitutes a good start in
genome scale modeling in cancer metabolisms, our reconstruction
and modeling is far from complete [36], and improvements,
additional tests and more specific studies should be undertaken in
future. Between the most relevant issues we name the follows:
1) It has been reported that the expression of M2-PK,aspecific-
tumor pyruvate kinase, may enhance cell biosynthetic capabilities
by decreasing the transformation of phosphoenolpyruvate (PEP)
to pyruvate and shunting the intermediary substrates upstream
of PEP toward biosynthetic pathways required for cancer cell
growth [1,24]. This qualitative behavior was reproduced by
constraint-based modeling only when a proper ratio among
the objective function’s components is tune by one that may
quantify a more reliable conversion in cancer cell growth, see
Figure 6 D. According with previous studies, an isoform of
pyruvate kinase PKM1, PKM2, is highly represented during
cancer cell growth such that it induces a reduced metabolic
activity over pyruvate kinase producing a beneficial effects on
cancer cell growth [27]. Consistently with this fact, our model
can mirror this fact by identifying a region in phase plane
whose decreased activity of pyruvate kinase can induce an
Figure 6. Phenotype phase plane for glycolytic and TCA cycle enzymes. Panel (A) is a three-dimensional representation of how metabolic
activity of succinate dehydrogenase and glucose uptake rate influence growth. As Panels (B) and (C) show, in silico modeling leads us to identify some
regions where variations on pyruvate dehydrogenase and fumarate hydratase, both associated with tumor suppressor activity, can result in different
phenotypes. White lines indicate the direction at which the metabolic fluxes increase; black lines, the direction at which they decrease. The potential
effect that pyruvate kinase activity can produce on cancer cell growth is depicted in (D). In panel (D) objective function components were selected as
follows: cATP=12.47, cLactate=0.13, cNADPH=0.93, cR5P=0.6, cNAD=0.89, cOAA=0.75, cATP[m]=17.09 and cCitrate=0.55. The threshold flux activity is
denoted by a red line.
doi:10.1371/journal.pone.0012383.g006
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switching between PKM1 and PKM2 during cell transforma-
tion. An inverse effect on cancer cell growth is observed at a
threshold activity of PKM1, red line in Figure 6(D), a result
that requires of additional experimental studies. This result
makes evident the need of determining proper coefficients in
the objective function’s components to obtain meaningful
biological interpretations, specially when exploring the finest
of details in metabolic behavior.
2) In this study, we have selected a partial metabolic
reconstruction in order to permit a comparison between in
silico predictions and published findings in literature, such
that, this approach facilitated a reliable assessment of the in
silico results, see Figure 7. This primer modeling functions as a
benchmarks that will allow us to sequentially introduce other
pathways into the description. The reconstructed human
metabolic network [36] constitutes an excellent source for
extending our studies and potentially evaluate the role that
new pathways have to sustain cancer phenotype.
3) From a genetic point of view, over expression of oncogenes and/
or dysfunction of tumor repressors induce changes in genetic
circuits that trigger the temporal transition between normal and
cancer cell phenotype. Additional analysis will be required to
explore how regulatory networks will constrain metabolic
phenotype [37,38] and to what extent the development of
dynamic formalism can contribute to unraveling the main
principles behind the robustness of cancer cells [39,40]. In our
opinion, both issues are relevant to distinguish the biological
mechanism governing proliferation in cancer and normal
functioning cell from a systems biology point of view.
Methods
Flux Balance Analysis
Constraint-based modeling is a computational frame for
analyzing and exploring the phenotype space of metabolic
networks obeying mass conservation and steady-state assumption
[21,22]. Thus, beginning from metabolic reconstruction of cancer
cells, we applied linear programming to identify those metabolic
fluxes (nj, j=1,2…n) that maximize biomass production when
constrained by thermodynamics and mass balance principles;
max biomass~
X
i~1
ci:Xi
"#
such that
P
Si,j:nj~0 i~1,2:::m
{ajƒnjƒbj j~1,2:::n
where Si,j represents the stoichiometric coefficient of metabolite i
participating in the j reaction. In addition, biomass is represented
by a linear combination of metabolites essential to cell growth (Xi)
and whose contribution to biomass production are weighted by
coefficients (ci). Irreversible constraints and enzyme capacities for
each metabolic reaction are quantified by parameters aj and bj.
Dynamic Flux Balance Modeling
To model the temporal growth rate, we have assumed that
along the time line, it is possible to identify a time scale, Dt, where
the steady-state condition can be applicable. Briefly, assuming that
at the moment of initiation, the cell environment has a glucose
concentration, s
o
c and a cell density X0, the algorithm underlying
dynamic constraint-based modeling consists of an iterative process
among the following steps [21]. 1) Glucose concentrations sc
available for the cell must be identified. 2) The glucose
concentration then should be scaled to define quantity available
per unit of biomass and per unit of time:
sav~
sc
X:Dt
where sav denotes the initial concentration of glucose available in
Figure7.Physiologicalassessmentofinsilicointerpretations.A properassessmentofinsilicoresults isrequiredtoensureproperreconstruction.
Ten proofs were used here to evaluate the physiological consistency of the results from constraint-based modeling. In sequential order, columns
indicate the metabolic property computationally analyzed, in silico predictions and its consistency with some representative references. The blue text in
column 1 represents metabolic pathways, while red lines indicate the effects that enzyme mutation has on cancer cell growth.
doi:10.1371/journal.pone.0012383.g007
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metabolism, maximal growth rate, m, at the interval of time Dt is
calculated through the linear programming algorithm [21,23] and
consequently growth rate and the new substrate glucose uptake
rate Su are updated. 4) At the next described time step (t+Dt),
glucose concentration is obtained through the solution of the
classic set of differential equations:
dX
dt
~mX?X~X0 em Dt
LSc
L t
~Su:X?Sc~Scoz
Su
m
Xo 1{em Dt   
where X is the cell density, Su is the available concentration of
glucose and m represents the growth rate. In our simulation, the
algorithm was repeated until null concentration of glucose was
reached. The algorithm was implemented using Cobra Toolbox
package in Matlab software [28].
Flux Variability and Enzyme Essentiality analysis
Flux Variability analysis was applied to explore metabolic
redundancy in optimal phenotype. Thus, this procedure identifies
the range of numerical values for each flux over the reconstruc-
tion, while still satisfying the given constraints and optimizing a
selected objective function [23]. Enzyme essentiality analysis was used
to quantify to what extent the deletion of an enzymatic reaction
affects the optimization of selected objective function. In order to
identify those metabolic reactions obeying low flux variability and
high essentiality we selected two threshold values. First, we defined
as essential those metabolic reactions whose deletion reduced by
50% or more the original objective function. Second, reactions
with low flux variability were those whose absolute values on flux
variability were less or equal to 50% of the maximal flux variation
along the entire distribution. Those reactions intersecting both sets
constituted the target enzymes reported in Figures 3 and 4. Both
computational analyses were accomplished in a Matlab environ-
ment and COBRA toolbox.
Sampling null space of the stoichiometric matrix
The identification of metabolic fluxes (n) obeying the steady-
state condition, S:n~0,with S as the stoichiometric matrix, was
accomplished by sampling the null space of S by an Artificial
Center Hit and Run Algorithm (ACHR) [41,42]. Basically, this
algorithm defines an initial point along the null space of S. Once
this point is defined, the algorithm calculates ‘‘warm-up’’ points by
an iterative procedure. These warm-up points are stored in a
matrix W by which a centroid xc is calculated. Finally the sample
points are calculated by selecting one point yn in the W matrix and
moving in the direction vector given by (xc2y). The new vector
yn+1 is substituted by the previous point yn in W. The centroid is
recalculated, and this process continues iteratively until a desired
number of sample points are reached. ACHR was done using the
COBRA tool box [28]. Overall, 10,000 sampled points belonging
to the null space of the stoichiometric matrix were included in the
analysis.
Comparative analysis between in silico and experimental
growth kinetics
To verify that the kinetic growth curve obtained in silico can
exhibit a comparable behavior with the experimentally obtained
growth curve from Hela cell lines, we have applied a normalization
procedure in both curves. We have denoted G as a cell growth
matrix whose entry gi,j represents the j replicate of cellular density
measured at time i, with i=1….5 (five days) and j=1…6 (six
replicates per day). In addition, ,A. represents the average
growth vector whose entries Ai indicate the average over rows of
G. The normalization applied on both curves, theoretical and
experimental, was obtained through this transformation
ANorm
i ~
Ai{min(Ai)
max(Ai{min(Ai))
where Ai represents the average cellular density at sample i, and
min and max represent the minimal and maximal numerical value
of the i row of ,A.. In other words, above normalization permits
selection of a framework in which the minimal value of Ai
Norm is
equal to zero and a maximal value equal to a unit.
Microarray analysis
In order to have an idea of how cancer heterogeneity can
influence metabolic phenotype, we accomplished a statistical
analysis of microarray data on 33 samples of cervical uterine
cancer among 16 women patients. The analysis used previously
published microarray data [18] stored in GEO (repository at
NCBI under accession GSE5787) and analyzed in R with affy
package in bioconductors, http://www.bioconductor.org/. To
identify those genes that significantly vary with in the 33
samples, a t-statistics was accomplished selecting those genes
with a log-ratio higher than 1.2 and a p-value less than 0.01.T h e
set of genes identified and its corresponding information (such
as symbol, description, reference chromosome location, gene
ontology, and participation in metabolic pathways) are shown
in Table S2.
Cell Culture Conditions and Growth Kinetics
Growth rate were obtained through standard technique of
crystal violet procedure. The cell line HeLa was obtained from the
Unidad de Diferenciacion Celular y Ca ´ncer at FES-Zaragoza
UNAM. Cancer cell line was cultured in RPMI-advanced 1640
serum-free media (Gibco BRL, USA) with red phenol and
antibiotic-antimycotic solution (10,000 units penicillin, 10 mg
streptomycin, and 25 mg amphotericin B per mL). The cells were
incubated in 5% of CO2 and humidity saturation at 37uC. Cells
were cultured in 1mL of RPMI-Advanced medium in 24-well cell
culture plates (BD Falcon, USA) starting from an estimated
cellular population of 10
5 cells. Every day the medium for 6
different wells was removed and 100uL of glutaraldehyde at 1.1%
were added, until you have enough samples to complete the
kinetics. After this the glutaraldehyde is removed from each well
and the plate is left at room temperature until dryness is reached.
Violet crystal at 0.1% is added during 20 minutes and the wells are
then washed with bidistillate water. The water is removed and
then citric acid at 10% was added and shaken during 20 minutes.
The absorbance at 600 nm was obtained for the supernadant in
each well.
Supporting Information
Table S1 Metabolic reconstruction for central metabolism in
cancer.
Found at: doi:10.1371/journal.pone.0012383.s001 (0.03 MB
XLS)
Table S2 Genes with a significative variation on gene expression
in cervical cancer.
Found at: doi:10.1371/journal.pone.0012383.s002 (0.51 MB
XLS)
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